Lipidor is on right track

Today Lipidor announced its Q2 results and at LSIF we are pleased to see that Lipidor is on the right track both financially, with good cost control and equally importantly in terms of progress in the Phase III study. We look forward to hopefully getting updated information as the study progresses, and it will be interesting to see if the company can continue to deliver on the very tight timeline it has set for the study. If successful, AKP02 will mean so much to so many psoriasis patients.